JP5485893B2 - 医薬品の製造のためにプリン誘導体を使用する方法 - Google Patents

医薬品の製造のためにプリン誘導体を使用する方法 Download PDF

Info

Publication number
JP5485893B2
JP5485893B2 JP2010524542A JP2010524542A JP5485893B2 JP 5485893 B2 JP5485893 B2 JP 5485893B2 JP 2010524542 A JP2010524542 A JP 2010524542A JP 2010524542 A JP2010524542 A JP 2010524542A JP 5485893 B2 JP5485893 B2 JP 5485893B2
Authority
JP
Japan
Prior art keywords
compound
formula
hydrate
ester
chronic lymphocytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010524542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539146A (ja
JP2010539146A5 (enExample
Inventor
マイヤー，ローラン
ベッタイブ，カリマ
ガロン，エルベ
オーマタ，ナッシマ
ベルト，クリスティアン
レスター，カリーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Descartes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2010539146A publication Critical patent/JP2010539146A/ja
Publication of JP2010539146A5 publication Critical patent/JP2010539146A5/ja
Application granted granted Critical
Publication of JP5485893B2 publication Critical patent/JP5485893B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010524542A 2007-09-12 2008-09-12 医薬品の製造のためにプリン誘導体を使用する方法 Expired - Fee Related JP5485893B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0706390A FR2920776B1 (fr) 2007-09-12 2007-09-12 Utilisation de derives de purine pour la fabrication d'un medicament
FR0706390 2007-09-12
PCT/FR2008/001278 WO2009068761A2 (fr) 2007-09-12 2008-09-12 Utilisation de derives de purine pour la fabrication d'un medicament

Publications (3)

Publication Number Publication Date
JP2010539146A JP2010539146A (ja) 2010-12-16
JP2010539146A5 JP2010539146A5 (enExample) 2012-03-22
JP5485893B2 true JP5485893B2 (ja) 2014-05-07

Family

ID=39382006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524542A Expired - Fee Related JP5485893B2 (ja) 2007-09-12 2008-09-12 医薬品の製造のためにプリン誘導体を使用する方法

Country Status (13)

Country Link
US (1) US8431583B2 (enExample)
EP (1) EP2187889B1 (enExample)
JP (1) JP5485893B2 (enExample)
KR (1) KR20100075908A (enExample)
CN (1) CN101918000B (enExample)
BR (1) BRPI0816810A2 (enExample)
CA (1) CA2699590A1 (enExample)
DK (1) DK2187889T3 (enExample)
ES (1) ES2444419T3 (enExample)
FR (1) FR2920776B1 (enExample)
MX (1) MX2010002680A (enExample)
RU (1) RU2500400C2 (enExample)
WO (1) WO2009068761A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
WO2013130461A1 (en) * 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
GB0315259D0 (en) 2003-06-30 2003-08-06 Cyclacel Ltd Use
AU2004264419B2 (en) * 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament

Also Published As

Publication number Publication date
ES2444419T3 (es) 2014-02-25
KR20100075908A (ko) 2010-07-05
DK2187889T3 (da) 2014-02-03
BRPI0816810A2 (pt) 2017-05-16
RU2500400C2 (ru) 2013-12-10
CA2699590A1 (fr) 2009-06-04
WO2009068761A3 (fr) 2010-01-07
RU2010108505A (ru) 2011-10-20
FR2920776A1 (fr) 2009-03-13
CN101918000B (zh) 2012-11-21
EP2187889A2 (fr) 2010-05-26
CN101918000A (zh) 2010-12-15
US20100311768A1 (en) 2010-12-09
EP2187889B1 (fr) 2013-11-06
JP2010539146A (ja) 2010-12-16
MX2010002680A (es) 2010-08-26
FR2920776B1 (fr) 2012-09-28
WO2009068761A2 (fr) 2009-06-04
US8431583B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
EP1838320B1 (en) Cxcr4 antagonists for the treatment of medical disorders
US8114884B2 (en) CXCR4 antagonists for the treatment of medical disorders
RU2450000C2 (ru) N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3
CN114522167A (zh) Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CN114007621A (zh) 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂
EP3858833B1 (en) Aminonorbornane derivative and manufacture method thereof and use thereof
JP2025078745A (ja) キナーゼ阻害剤
EP3452484B1 (en) Certain protein kinase inhibitors
JP5485893B2 (ja) 医薬品の製造のためにプリン誘導体を使用する方法
CN115785107B (zh) 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
JP2024503021A (ja) Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法
JP6013498B2 (ja) リンパ増殖性悪性疾患の治療のためのホスファチジルイノシトール３−キナーゼ阻害剤としてのｎ−（３−｛［（３−｛［２−クロロ−５−（メトキシ）フェニル］アミノ｝キノキサリン−２−イル）アミノ］スルホニル｝フェニル）−２−メチルアラニンアミド
JPH01501477A (ja) 抗葉酸剤
EP3397627B1 (en) Indolizine derivatives, composition and methods of use
JP2014515026A (ja) アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法
WO2022268065A1 (en) Compounds as erk inhibitors
US10774075B2 (en) Compounds for treating rac-GTPase mediated disorder
WO2019246427A1 (en) Crystalline forms of pyridinone-containing tricyclic compounds and methods of preparing and using same
CN119630393A (zh) 抗微生物化合物
WO2009105238A2 (en) Kinase protein binding inhibitors
WO2020046941A1 (en) Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same
HK40046113A (en) Heteroaryl-substituted pyrazole compound and medicinal use thereof
CN1990462A (zh) 琥珀酰肼类化合物及其组合物在制备治疗抗白血病药物方面的应用
CN101137379A (zh) 用于治疗医学病症的cxcr4拮抗剂
OA16810A (en) N- (3- {[(3- {[2-chloro-5-(methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phenyl) 2 -methylalaninamide as phosphatidylinositol 3 kinase inhibitor for the treatment of lymphoproliferative malignancies.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131022

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140220

R150 Certificate of patent or registration of utility model

Ref document number: 5485893

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees